▎ 摘　　要

NOVELTY - Biosensor system comprises blue graphene quantum dots immobilized with an antibody specific to estrogen receptor-α and a fluorescent dye 9-6-(2, 5- dioxopyrrolidin-1-yl)oxy-6-oxohexyl-8, 8-dimethyl-2-oxo-4- (trifluoromethyl)pyrano3, 2-gquinolin-6-ylmethane sulfonate triethylazanium, where the graphene quantum dots transfer resonance energy to the dye. USE - Biosensor system used in fluorescence resonance energy transfer assay kit for detection of estrogen receptor-α or progesterone, or detection of breast cancer biomarkers in a sample (all claimed). ADVANTAGE - The biosensor system provides identification of biomarkers with high sensitivity, efficiency and specificity. The method is rapid, reliable and cost-effective. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) a biosensor system, which comprises green graphene quantum dots immobilized with an antibody specific to progesterone and a fluorescent dye rhodamine 6G or 9- (2- ethoxycarbonyl phenyl)-6- (ethylamino)-2, 7-dimethylxanthen-3-ylidene- ethylazanium chloride; (2) a fluorescence resonance energy transfer assay kit for detection of estrogen receptor-α, which comprises blue graphene quantum dots an antibody specific to estrogen receptor-α and a fluorescent dye Alexa fluor430 or 9-6- (2, 5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl-8, 8-dimethyl-2-oxo-4- (trifluoromethyl)pyrano3, 2-gquinolin-6-ylmethane sulfonate triethylazanium; (3) a method for performing fluorescence resonance energy transfer assay which involves: (a) preparing blue graphene quantum dots by oxidation; (b) immobilizing antibody specific to estrogen receptor -α on the blue graphene quantum dots to give antibody immobilized blue graphene quantum dots; (c) incorporating a fluorescent dye 9-6- (2, 5-dioxopyrrolidin-1- yl)oxy-6-oxohexyl-8, 8-dimethyl-2-oxo-4- (trifluoromethyl)pyrano3, 2- gquinolin-6-ylmethane sulfonate triethylazanium or Alexa fluor930 with a sample in the presence of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/Succinimidyl ester (NHS); (d) mixing the antibody immobilized blue graphene quantum dots with the solution to bring the graphene dots and dye in proximity; and (e) measuring emission spectrum of the mixture; (4) an in vitro method for detecting breast cancer biomarkers in a sample which involves: (a) mixing a sample from a subject with 9-6- (2, 5-dioxopyrrolidin-1- yl)oxy-6-oxohexyl-8, 8-dimethyl-2-oxo-4- (trifluoromethyl)pyrano3, 2- gquinolin-6-ylmethane sulfonate triethylazanium or Alexa fluor930 in the presence of EDC/NHS leading to tagging of the dye by an antigen estrogen receptor-α if present in the sample, or mixing a sample from a subject with dye rhodamine 6Gin the presence of EDC/NHS leading to tagging of the dye by an antigen Progesterone if present in the sample; (b) introducing anti Estrogen receptor-α (ERα) antibody immobilized blue graphene quantum dot into the mixture, or introducing Anti-progesterone antibody immobilized green graphene quantum dot into the mixture; and (c) measuring the emission spectra of the sample to determine the presence of estrogen receptor-α or progesterone; and (5) a method for performing fluorescence resonance energy transfer assay which involves: (a) preparing green graphene quantum dots by oxidation; (b) immobilizing antibody specific to progesterone on the green graphene quantum dots to give antibody immobilized green graphene quantum dots; (c) incorporating a fluorescent dye rhodamine 6G with a sample in the presence of EDC/NHS; (d) mixing the antibody immobilized green graphene quantum dots with the solution to bring the graphene dots and dye in proximity; and (e) measuring emission spectrum of the mixture.